Anti-GM-CSF Antibody Measurement for IBD Relapse Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tools lack sufficient accuracy to predict relapse or sustained remission in inflammatory bowel diseases (IBD), making it challenging to select appropriate therapies effectively.
Innovation Solution
Measuring the level of anti-GM-CSF antibodies in a subject's sample to determine IBD relapse risk, allowing for the selection of appropriate treatments based on the predicted risk, including comparing antibody levels over time and using additional biomarkers like fecal S100A8/A9.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standardized care is provided to IBD patients, then treatment coverage is ensured, but relapse prediction accuracy remains insufficient
Solution Approach 1:
The patent changes the parameter being measured from general inflammatory markers to specific anti-GM-CSF antibody levels. This parameter change enables more accurate relapse prediction by focusing on the specific immune mechanism underlying IBD relapse, thereby resolving the contradiction between prediction accuracy and diagnostic complexity.
Solution Approach 2:
The patent replaces complex clinical assessment mechanisms with a simplified immunological assay. Instead of relying on multiple clinical parameters and subjective assessments, the invention uses a direct measurement of anti-GM-CSF antibodies, substituting a complex diagnostic system with a more precise and manageable biochemical test.
2Reliability
If anti-TNF therapy is introduced early, then sustained remission rates improve, but treatment selection accuracy lacks guidance
Solution Approach 1:
The patent segments the IBD patient population into distinct subsets based on their anti-GM-CSF antibody profiles. This segmentation allows for differentiated treatment selection, where patients with high antibody levels can be identified as likely responders to anti-TNF therapy, thereby preventing loss of information about patient heterogeneity and enabling more reliable treatment outcomes.
3Loss of time
If monitoring frequency is increased to detect relapse early, then intervention timing improves, but resource utilization increases
Solution Approach 1:
The patent implements preliminary action by measuring anti-GM-CSF antibody levels before clinical relapse symptoms appear. This early detection capability allows for timely intervention without requiring frequent monitoring, as the biomarker provides advance warning of impending relapse. This resolves the contradiction by enabling effective early detection while maintaining resource efficiency through targeted rather than routine monitoring.
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2A~2B
AI summary
Described are methods and compositions for evaluating the relapse risk in subjects having an inflammatory bowel disease (IBD) by measuring the level of an anti-GM-CSF antibody in a sample from said subject, thereby determining the IBD relapse risk for said subject. Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject. Some such methods include providing the result of said measuring to a party in order for said party to evaluate IBD relapse risk for said subject; or providing the IBD relapse risk to a party in order for said party to select a treatment for said subject.